News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pulmonx, Inc. Reports Scientific Publication and Presentations Highlighting Key Advances in Emphysema Treatment



9/28/2010 11:48:57 AM

NEUCHÂTEL, Switzerland--(BUSINESS WIRE)--Pulmonx, an emerging leader in interventional pulmonology, announced today that the New England Journal of Medicine has published the results of the largest prospective, randomized, controlled study completed to date of endobronchial approaches to emphysema treatment, the VENT Study (Endobronchial Valve for Emphysema PalliatioN Trial). The published results of the VENT Study highlight the potential of the Pulmonx Zephyr® Endobronchial Valve (EBV) to improve the lives of patients suffering with certain types of emphysema. In the days leading up to the publication, several physician investigators also presented results of the European arm of the study, known as EURO-VENT, at the annual meeting of the European Respiratory Society (ERS) in Barcelona, Spain. The EURO-VENT data confirmed most of the positive results of the U.S. VENT Study and offered new analyses that highlight significant clinical benefits linked to target lung lobe volume reduction.

Read at BioSpace.com


comments powered by Disqus
   
Emphysema

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES